Synthesis and evaluation of pyrazolo[3,4-b]pyridine CDK1 inhibitors as anti-tumor agents.
A series of 3,5-disubstituted pyrazolo[3,4-b]pyridine cyclin-dependent kinase (CDK) inhibitors was synthesized. These compounds showed potent and selective CDK inhibitory activities and inhibited in vitro cellular proliferation in cultured human tumor cells. Selected compounds were evaluated in an in vivo tumor xenograft model. The synthesis and biological evaluation of these pyrazolo[3,4-b]pyridines and related compounds are reported.
Lin
Ronghui
R
Johnson & Johnson Pharmaceutical Research & Development L.L.C., 1000 Route 202, PO Box 300, Raritan, NJ 08869, USA. Ronghui.Lin@yahoo.com
Connolly
Peter J
PJ
Lu
Yanhua
Y
Chiu
George
G
Li
Shengjian
S
Yu
Yang
Y
Huang
Shenlin
S
Li
Xun
X
Emanuel
Stuart L
SL
Middleton
Steven A
SA
Gruninger
Robert H
RH
Adams
Mary
M
Fuentes-Pesquera
Angel R
AR
Greenberger
Lee M
LM
D000970:Antineoplastic Agents / Q000138:chemical synthesis* / Q000737:chemistry / Q000494:pharmacology*; D016203:CDC2 Protein Kinase / Q000037:antagonists & inhibitors*; D002478:Cells, Cultured; D006801:Humans; D047428:Protein Kinase Inhibitors / Q000138:chemical synthesis* / Q000737:chemistry / Q000494:pharmacology*; D011720:Pyrazoles / Q000138:chemical synthesis* / Q000737:chemistry / Q000494:pharmacology*; D011725:Pyridines / Q000138:chemical synthesis* / Q000737:chemistry / Q000494:pharmacology*
D000970:Antineoplastic Agents; D047428:Protein Kinase Inhibitors; D011720:Pyrazoles; D011725:Pyridines; C447480:pyrazolo(3,4-b)pyridine; D016203:CDC2 Protein Kinase